GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Third Quarter Ended September 30, 2019 Epidiolex U.S. year to date net sales of $188.0 million, including Q3...

GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy Cannabidiol oral solution is the...

GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2019 Epidiolex U.S. Q2 net sales of $68.4 million Positive CHMP opinion clears...

GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2019 Epidiolex U.S. Q1 net sales of $33.5m  Positive Phase 3 pivotal results...

GW Pharmaceuticals Receives Orphan Drug Designation from FDA for Cannabidiol for the Treatment of Tuberous Sclerosis Complex LONDON, April 21, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP)...